Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant WIDER study of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer
MOH_2024-02-14_013226Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-02-14_013226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-14_013226.